Severe Liver Dysfunction After Raltitrexed Administration in an HCV-Positive Colorectal Cancer Patient

LETTER TO THE EDITOR

D. Santini Università Campus Bio-Medico, Rome, Italy

A. Picardi Università Campus Bio-Medico, Rome, Italy

B. Vincenzi Università Campus Bio-Medico, Rome, Italy

P. Binetti Università Campus Bio-Medico, Rome, Italy

C. Massacesi Divisione di Oncologia Speciale Medica, Ospedale Regionale Umberto I, Ancona, Italy

A. La Cesa Università Campus Bio-Medico, Rome, Italy

G. Tonini Università Campus Bio-Medico, Rome, Italy

show all

REFERENCES

Judson I.R. ‘Tomudex’ (raltitrexed) development: preclinical, phase I and II studies. Anticancer Drugs 1997; 8: 5–9
PubMedGoogle Scholar
Raderer M., Fiebiger W., Wrba F., Scheithauer W. Fatal liver failure after the administration of raltitrexed for cancer chemotherapy: a report of two cases. Cancer 2000; 15: 890–892
Google Scholar
Yeo W., Chan P.K., Zhong S., Ho W.M., Steinberg J.L., Tam J.S., Hui P., Leung N.W., Zee B., Johnson P.J. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J. Med. Virol. 2000; 62: 299–307
PubMed Web of Science ®Google Scholar
Saif M.W., Little R.F., Hamilton J.M., Allegra C.J., Wilson W.H. Reactivation of chronic hepatitis B infection following intensive chemotherapy and successful treatment with lamivudine: a case report and review of the literature. Ann. Oncol. 2000; 12: 123–129
Web of Science ®Google Scholar
de Gramont A., Figer A., Seymour M., et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J. Clin. Oncol. 2000; 18: 2938–2947
PubMed Web of Science ®Google Scholar
Gribaudo G., Riera L., Lembo D., De Andrea M., Johnson L.F., Landolfo S. The anticytomegaloviral activity of raltitrexed is abrogated in quiescent mouse fibroblasts that overexpress thymidylate synthase. Virus Res. 2001; 73: 57–65
PubMed Web of Science ®Google Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Severe Liver Dysfunction After Raltitrexed Administration in an HCV-Positive Colorectal Cancer Patient

LETTER TO THE EDITOR

REFERENCES

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Severe Liver Dysfunction After Raltitrexed Administration in an HCV-Positive Colorectal Cancer Patient

LETTER TO THE EDITOR

REFERENCES

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date